Wall Street analysts expect that Vital Therapies, Inc. (NASDAQ:VTL) will announce earnings per share (EPS) of ($0.30) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Vital Therapies’ earnings. Vital Therapies reported earnings of ($0.37) per share during the same quarter last year, which indicates a positive year over year growth rate of 18.9%. The business is scheduled to issue its next quarterly earnings results on Tuesday, March 6th.
According to Zacks, analysts expect that Vital Therapies will report full year earnings of ($1.29) per share for the current year, with EPS estimates ranging from ($1.33) to ($1.26). For the next year, analysts anticipate that the firm will post earnings of ($1.36) per share, with EPS estimates ranging from ($1.54) to ($1.21). Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that follow Vital Therapies.
Vital Therapies (NASDAQ:VTL) last issued its quarterly earnings results on Wednesday, October 25th. The company reported ($0.30) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.32) by $0.02. During the same period in the prior year, the firm posted ($0.32) earnings per share.
A number of brokerages recently commented on VTL. Zacks Investment Research cut Vital Therapies from a “hold” rating to a “sell” rating in a research report on Tuesday, October 31st. ValuEngine upgraded Vital Therapies from a “strong sell” rating to a “sell” rating in a research report on Saturday, October 21st. Finally, BidaskClub upgraded Vital Therapies from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 5th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. Vital Therapies has a consensus rating of “Hold” and a consensus target price of $8.00.
Vital Therapies (NASDAQ:VTL) opened at $6.35 on Monday. Vital Therapies has a 12-month low of $2.25 and a 12-month high of $6.50.
COPYRIGHT VIOLATION NOTICE: “-$0.30 Earnings Per Share Expected for Vital Therapies, Inc. (VTL) This Quarter” was originally posted by Week Herald and is the property of of Week Herald. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://weekherald.com/2017/11/15/0-30-earnings-per-share-expected-for-vital-therapies-inc-vtl-this-quarter.html.
In other Vital Therapies news, Director Muneer A. Satter acquired 130,000 shares of Vital Therapies stock in a transaction that occurred on Thursday, September 14th. The shares were acquired at an average cost of $4.01 per share, with a total value of $521,300.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jean Jacques Bienaime acquired 10,000 shares of Vital Therapies stock in a transaction that occurred on Wednesday, September 13th. The stock was acquired at an average cost of $4.00 per share, for a total transaction of $40,000.00. Following the completion of the purchase, the director now directly owns 65,119 shares of the company’s stock, valued at $260,476. The disclosure for this purchase can be found here. Insiders purchased 190,000 shares of company stock worth $737,800 over the last ninety days. 32.60% of the stock is currently owned by insiders.
A number of large investors have recently added to or reduced their stakes in the stock. FMR LLC boosted its stake in Vital Therapies by 102.9% in the first quarter. FMR LLC now owns 2,957,878 shares of the company’s stock valued at $11,832,000 after buying an additional 1,500,000 shares in the last quarter. Victory Capital Management Inc. boosted its stake in shares of Vital Therapies by 0.9% during the third quarter. Victory Capital Management Inc. now owns 2,603,089 shares of the company’s stock valued at $13,145,000 after purchasing an additional 23,810 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Vital Therapies by 261.4% during the second quarter. Goldman Sachs Group Inc. now owns 233,250 shares of the company’s stock valued at $676,000 after purchasing an additional 168,705 shares in the last quarter. LMR Partners LLP acquired a new stake in shares of Vital Therapies during the second quarter valued at about $396,000. Finally, Blair William & Co. IL boosted its stake in shares of Vital Therapies by 67.2% during the second quarter. Blair William & Co. IL now owns 99,500 shares of the company’s stock valued at $289,000 after purchasing an additional 40,000 shares in the last quarter. 25.58% of the stock is currently owned by institutional investors and hedge funds.
Vital Therapies Company Profile
Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vital Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.